Furthermore, TNKS1BP1 knockdown synergized with anti-PD-L1 treatment by upregulating PD-L1 expression on tumor cells via the JAK2/STAT3 pathway and augmenting the infiltration and effector function of cytotoxic T lymphocytes (Fig. 8). Here, JAK2 is linked to neoplasm.